The quarter missed on the one reported financial benchmark. GAAP loss per share was $1.19, versus published consensus of roughly $0.97; the loss also widened from $0.75 a year earlier. The miss reflects a sharp ramp in clinical-development spending rather than a revenue shortfall—Rapport remains a clinical-stage company without product revenue.
| Metric | Q2 2026 | Comparison | What changed |
|---|---|---|---|
| Net loss per share | $(1.19) | Consensus: about $(0.97); Q2 2025: $(0.75) | Worse than both expectations and prior year (Statement of Operations) |
| Net loss | $(56.6M) | Q2 2025: $(26.7M) | More than doubled as the development program expanded (Statement of Operations) |
| R&D expense | $51.4M | Q2 2025: $22.7M | Spending ramped with pivotal-trial and pipeline activity (Statement of Operations) |
| Cash, equivalents and short-term investments | $436.1M | $476.8M at March 31, 2026 | Down $40.7M sequentially, while runway guidance was retained (Financial Results; Cash Flow statement) |
| Cash runway | Into 2H 2029 | Unchanged from the prior update | No new financing need was introduced (Cash Runway) |
The headline clinical milestone was delivered, but it was already expected. FOCUS 1 and FOCUS 2 are now enrolling in Phase 3 for focal onset seizures, matching management's prior target to initiate the program in the second quarter. China IND clearance and enrollment in the long-term safety study reinforce execution, but the filing brings no new controlled efficacy data or accelerated pivotal timeline. That makes this progress supportive of the existing thesis, not a fresh clinical upside surprise (Corporate Highlights — RAP-219 in Epilepsy).
Previously disclosed Phase 2 follow-up data should not be treated as new de-risking. The release repeats April-presented open-label results, including median clinical-seizure reductions of 90% in weeks 9–12 and 59% in weeks 13–16. The updated 22-day half-life estimate may support less-frequent dosing potential, but it is pharmacokinetic modeling rather than a new efficacy readout (Corporate Highlights — Follow-up Phase 2a Data; RAP-219 Half-Life).
The next genuine value-setting event is still ahead. Bipolar-mania Phase 2 topline data remain due in October 2026. Increasing enrollment and revising the statistical plan could allow a successful study to serve as confirmatory evidence, but that is only an option contingent on the data; the filing does not reduce that clinical risk today (Additional Pipeline Updates — Bipolar Mania Phase 2 Trial).
Net: the company preserved its long cash runway and executed against the expected Phase 3 start, but the earnings loss was worse than consensus and no new efficacy catalyst arrived.
Read the original 8-K on SEC EDGAR ↗